Loss of exclusivityJuly 2034latest FDA-listed patent expiry
CompanyEMERGENT BIODEFENSE OPERATIONS LANSING LLC
Drug detail
Brand name
TEMBEXA
Active ingredient
BRINCIDOFOVIR
Strength
10MG/ML
Dosage form
SUSPENSION
Route
ORAL
Modality
Small molecule
FDA approval
June 2021
Marketing status
RX
Listed patents
Patent
Expires
Type
9303051
July 2034
substance, product
Regulatory exclusivity
Code
Expires
ODE-354
June 2028
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.
TEMBEXA patent cliff — loss of exclusivity July 2034 | CliffBio